Organization
UCB Pharma, N/A, Slough, United Kingdom
3 abstracts
Abstract
ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2Org: UCB Pharma, N/A, Brussels, Belgium, UCB Pharma, N/A, Monheim am Rhein, Germany, UCB Pharma, N/A, Slough, United Kingdom,
Abstract
BIMEKIZUMAB TREATMENT RESULTED IN CLINICALLY MEANINGFUL IMPROVEMENTS IN THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) SCORES USING POOLED RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH PSORIATIC ARTHRITISOrg: Sorbonne Université, N/A, Paris, France, AP-HP, Pitié-Salpêtrière Hospital, N/A, Paris, France, Oxford University Hospitals NHS Trust, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford, United Kingdom, Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States of America, Stichting Tools, Patient Research Partner, Amsterdam, Netherlands,
Abstract
BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIESOrg: Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet Herne, Bochum, Germany, Oregon Health & Science University, Arthritis and Rheumatic Diseases, Portland, United States of America, Leiden University Medical Center (LUMC), Department of Rheumatology, Leiden, Netherlands, University Hospitals, Case Western Reserve University, Cleveland, United States of America, University of Alberta, Department of Medicine, Edmonton, Canada,